drugset / Trial / NCT05601336

of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

NCT05601336

Phase 3 Unknown 200 enrolled Beni-Suef University
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and dapagliflozin as monotherapies and the effect of both of them as a combined therapy in infertile women with PCOs.

Timeline

Start
2022-01-15
Primary completion
2023-07-30
Completion
2023-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 5 mg
Comparator Dapagliflozin/Metformin Unknown
Comparator Metformin Small molecule 1000 mg

Indications

No indication recorded.